Análisis Argos
AMGN
AMGNCara1 señal de riesgo
Amgen Inc. · Healthcare
US$ 374.15
precio al 2026-07-04
Valor justo Argos*
US$ 266–300
vs. su valor justo
26% por encima
Score Argos
54/100
LA RESPUESTA
El mercado le pide crezca 12.7% al año — más de lo que ha demostrado (6%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
✓Las ganancias crecieron 89% el último año.
✓Retorno sobre el capital alto (17%).
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Balance frágil: la deuda pesa sobre el negocio.
!Crecimiento estancado o en baja.
!Altman Z'' en zona roja (0.26)
VALOR2/6FUTURO2/6PASADO5/6SALUD1/6DIVIDENDO3/6
El Iris de calidad
VALOR2/6FUTURO2/6PASADO5/6SALUD1/6DIVIDENDO3/6
ValorCerca de su valor justo
FuturoCrecimiento moderado
PasadoFundamentales sólidos y sostenidos
SaludBalance frágil
DividendoRetorno al accionista moderado
Score Argos54de 100Cara
Ingresos▲10%
US$ 36.7 B
Margen operativo▲34%
29.1%
Flujo de caja libre▼22%
US$ 8.1 B
Deuda neta
US$ 45.5 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 201.9B
P/E26.2x
EV/EBITDA15.6x
FCF yield4%
ROIC16.9%
Margen operativo29.1%
Crecim. ingresos+9.9%/año
Piotroski F8/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

zacks.com · 24 jun
Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know
In the most recent trading session, Amgen (AMGN) closed at $351.93, indicating a +1.42% shift from the previous trading day.
fool.com · 23 jun
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers.
zacks.com · 23 jun
Are Biosimilars Becoming a Key Pillar of Amgen's Growth Story?
AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.
fool.com · 23 jun
2 Underrated Weight Loss Stocks to Buy and Hold
They look well-positioned to grab a slice of the fast-growing anti-obesity market.
fool.com · 19 jun
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-to-patient model for tumor treatment, targeting niche oncology markets with tumor-treating electrical fields.
zacks.com · 19 jun
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
zacks.com · 17 jun
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
The latest trading day saw Amgen (AMGN) settling at $341.66, representing a -1.78% change from its previous close.
forbes.com · 17 jun
The Healthcare M&A Wave
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.